GP2

Across TCGA pan-cancer cohorts, GP2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of GP2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where GP2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GP2 is over-expressed in tumor, although a few such as PDAC and HNSC show the opposite, repressed pattern.

PDAC, HNSC, and COAD are the cancer types where GP2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GP2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	−2.439	<.001	9	view →
HNSC	Male	III,IV	−1.243	<.001	8	view →
COAD	All	All	−0.817	<.001	7	view →
LSCC	Male	All	−0.568	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

GP2–PDAC

Open the PDAC breakdown →